Yearly Archives: 2020


The biotech IPO boom is becoming ‘historic’ as four more throw their hats in – Endpoints News

Four more US biotechs filed to go public Friday as yet more companies clamber to get through a yawning IPO window and onto a market thats signaled its willingness to reward nearly any new drugmaker.

The new entrants are led by ALX Oncology and the biological analytics biotech Berkeley Lights, each of whom filed to raise $100 million. The autoimmune company Pandion Therapeutics also filed for $75 million, and Kiromic Biopharma, a tiny immuno-oncology startup based in San Antonio, filed for $25 million.

These companies will try to capitalize on a 2020 biotech IPO boom that the investment firm Renaissance Capital recently called historic. The spree began in January and, after a brief interlude when the pandemic first hit the US and Europe, has only picked up in the last two months. The 23 companies that have gone public averaged an 80% return on their offering price, according to Renaissance Capital numbers. Every single one priced above their midpoint or upsized their offering.

Unlike most of their fellow newly or would-be public biotechs, Berkeley Lights will enter the market with significant revenue on the books. The company doesnt make drugs but instead has built a digital cell biology platform that can analyze living cells from a variety of different dimensions and, in principal, accelerate drug development. Theyve partnered with Sanofi and Pfizer on antibody discovery and last year, signed a $150 million pact with Ginkgo Bioworks to help the synthetic biology unicorn advance its genetic engineering capabilities.

All told, the company earned $51 million in revenue last year. Unlike a drug developer, they have no cash earmarked for specific pipeline products, and said they will use proceeds for research, potential acquisitions and general corporate purposes.

For ALX Oncology, a successful offering would mean their second $100 million tranche of the year. In February, the California biotech raised $105 million to help advance its sole pipeline candidate: an antibody designed to target CD-47. Thats the same dont-eat-me signal targeted by Irv Weissmans Forty Seven Inc., the biotech Gilead paid $5 billion for in January. ALXs pitch is that their antibodys FC receptor is engineered to not attract macrophages, reducing toxicity. The biotech will use their proceeds to push the drug through its ongoinghead and neck squamous cell carcinomaand gastric cancer trial and begin new trials for it in acute myeloid leukemia and myelodysplastic syndrome. A portion is also earmarked for CMC work.

Founded out of Polaris in 2018, Pandion Therapeutics was tapped last year for an up-to $800 million partnership to help a reorganizing Astellas develop antibodies for auto-immune disorders. That deal included $45 million upfront and the company also earned $80 million from a Series B in April. The new funding will be used to push their lead molecule through Phase I/II trials in ulcerative colitis while also backing preclinical research, particularly on a pair of antibodies meant to turn on the PD-1 checkpoint and tamp down the immune system.

Kiromic, meanwhile, is in part just trying to stay alive. With less than $2 million 5 million when a subsequent $3 million Series B is included in the bank at years end, they acknowledged in their S-1 that theres substantial doubt regarding the Companys ability to continue as a going concern. In this climate, though, thats worked out just fine for other companies. Applied Molecular Transport went publicin May with the same concerns. They ultimately raised $177 million.

Link:
The biotech IPO boom is becoming 'historic' as four more throw their hats in - Endpoints News

Michael Schumacher is reportedly getting another stem-cell surgery; Journalist alleged it will be an experimental procedure – EconoTimes

Michael Schumacher is still surviving as he continues to battle complications from the near-fatal head injury he sustained while skiing in 2013. It was reported that the F1 legend is set to undergo another round of stem cell procedure that will help regenerate his nervous system.

Facts about the reported new operation on Schumi

With this surgery, his family and doctors are hoping that he will be able to recover functions in parts of his body. This is because it is aimed at his sensory system that was affected by his injuries.

The Daily Mail reported that currently, Michael Schumacher is being treated and cared for by French cardiologist Dr. Philippe Menasche, a medical expert specializing in stem cell research. It was revealed that a series of surgeries are needed for this treatment, so this is just one of the racing champs operations for his recovery.

In an article that appeared in an Italian publication Le Dauphine, it was reported that Dr. Menasche will do seminal heart surgery on Schumi in his next surgery schedule. It was added that this will take place soon, but the exact date was not revealed.

It is also believed that this will be the second time that the said doctor is operating on Michael Schumacher. The first procedure was said to have been done in September 2019, and Schumi was in the hospital for about three days. At any rate, in this operation, his damaged cells will be replaced with healthy ones that will be taken from his bone marrow.

An experimental stem-cell surgery?

Michael Schumacher has not recovered from his accident that happened more than six years ago. He is currently being treated in his own home in Switzerland, but his exact condition is still a mystery since his family continues to keep everything related to his health a secret.

Dr. Nicola Acciari, a leading neurosurgeon, previously claimed that Michael Schumacher has osteoporosis and suffering from muscle atrophy since he is unable to move for years. The goal is to regenerate Michaels nervous system, The Sun quoted him as saying in connection to the stem cell therapy.

However, Jean-Michel Dcugis, a French journalist, shared to British daily national newspaper, The Times, that the procedure is experimental at this point since Dr. Menasche is actually a cardiologist.

"Our sources say that Michael Schumacher is receiving stem cell perfusions that produce a systemic anti-inflammatory effect, The Sun quoted Dcugis as saying. "It's quite mysterious as Menasch works only on the heart. He is carrying out experiments with secretome that is made by a laboratory from new stem cells and injected into veins, until now only on animals.

Read the original post:
Michael Schumacher is reportedly getting another stem-cell surgery; Journalist alleged it will be an experimental procedure - EconoTimes

Human Embryonic Stem Cell Assay Market Valuation 2020 | Key Trends, Growth Drivers, In Depth Analysis, Solution and Businesss Opportunities – Apsters…

The orbisresearch.com has published Human Embryonic Stem Cell Assay market 2020 global trends and analysis report to its store

The Global Human Embryonic Stem Cell Assay market report is deep study of the present market dynamics. It consists of the detailed study of current market trends along with the past statistics. The past years are considered as reference to get the predicted data for the forecasted period. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A significant development has been recorded by the market of Human Embryonic Stem Cell Assay, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A systematized methodology is used to make a Report on the Global Human Embryonic Stem Cell Assay market. For the analysis of market on the terms of research strategies, these techniques are helpful. All the information about the Products, manufacturers, vendors, customers and much more is covered in research reports.

Request a pdf sample at

https://www.orbispharmareports.com/sample-request/19372

Browse the full report at

https://www.orbispharmareports.com/global-human-embryonic-stem-cell-assay-market-2020-2026-report-by-type-applications-manufacturers-and-regional-overview/

Key Segmentation:

Key Players: Thermo Fisher Scientific Merck GE Healthcare Bio-Rad Laboratories Promega Corporation Agilent Technologies Perkinelmer Miltenyi Biotec Cell Biolabs Hemogenix Stemcell Technologies Bio-Techne Corporation Cellular Dynamics International (CDI)

Types: Viability/Cytotoxicity Isolation & Purification Cell Identification Proliferation Differentiation Function Apoptosis

Key Applications: Biopharmaceutical & Biotechnology Companies Research Institutes

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. There is a target set in market that every marketing strategy has to reach. The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. SWOT analysis includes the study of Threats, weaknesses, strengths and opportunities that the Human Embryonic Stem Cell Assay market. Whereas PESTEL analysis is the study concerning Economic, Technological, legal political, social, environmental matters. For the analysis of market on the terms of research strategies, these techniques are helpful.

Have any inquiries on purchasing the report? If yes, then contact us @

https://www.orbispharmareports.com/enquiry-before-buying/19372

Potential consumers, market values, and the future scope for the Human Embryonic Stem Cell Assay market are explained thoroughly to the users in this report. The key players of Human Embryonic Stem Cell Assay industry, their product portfolio, market share, industry profiles is studied in this report. It is very important for the vendors to provide customers with new and improved product/ services in order to gain their loyalty. The study of various segments of the global market are also covered in the research report. In addition to that, for the forecast periods determination of factors like market size and the competitive landscape of the market is analyzed in the report. Due to the increasing globalization and digitization, there are new trends coming to the market every day. The research report provides the in-depth analysis of all these trends.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector Costello Senior Manager Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas 75204, U.S.A. Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155 Email ID: [emailprotected]

Original post:
Human Embryonic Stem Cell Assay Market Valuation 2020 | Key Trends, Growth Drivers, In Depth Analysis, Solution and Businesss Opportunities - Apsters...

Bone Marrow Transplantation Market Size : Technological Advancement and Growth Analysis with Forecast to 2028 – Owned

New York City, United States The effect of the coronavirus pandemic and the lockdown it activated is unmistakably obvious in budgetary markets. Yet, there is still no clearness on the more profound effect that it is having across organizations and modern areas. In view of evaluations made by various examiners and industry body Ficci, here is an effect investigation in human services area.

In addition to rapid expansion of bone marrow donor registry, increasing commercialization of cellular therapy and tissue engineering, increased survival rate post bone marrow transplant procedures, and easier access to treatment will be some of the most prominent factors driving thebone marrow transplantation market.

According to the latest research by Persistence Market Research, the global bone marrow transplantation market is expected to exceed US$ 12 Bn by the end of 2028. The bone marrow transplantation market is expected to grow at a CAGR of 3.6% through the forecast period 2018-2028.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4288

Company Profile

North America Will Continue to Lead the Pack in Bone Marrow Transplantation Market

Increasing per-capita healthcare and private insurance expenditure is a major factor that is expected to maintain the high demand for technologically advanced treatment procedures, such as bone marrow transplantation, over the forecast period. Increasing blood cancer cases and geriatric population are among the key factors expected to boost the demand for bone marrow transplantation in North America.

The increasing prevalence of myeloma in the region is leading to an increase in the execution of bone marrow transplantation procedures through the allogeneic method. Companies engaged in stem cell therapies are expanding their product portfolio to offer sound treatment solutions for diseases caused while undergoing the allogeneic transplant method.

The availability of more than 90% unrelated donors and high healthcare expenditure are among the factors driving the overall bone marrow transplantation market in North America at present.

The American Society for Blood and Marrow Transplant reported an increasing prevalence of leukemia and lymphoma in patients aged 65 years and above, and this age group constituted 25-30% of the total number of bone marrow transplantation recipients in 2014.

In 2015, the Senate and House of Representatives of the US reauthorized the Stem Cell Therapeutic and Research Act of 2005, which led to an increase in the US unrelated donors registry to 200,000 donors.

Germany Will Steer Europes Market for Bone Marrow Transplantation

Rise in per capita GDP is expected to improve the healthcare expenditure in countries such as Germany and Spain. Government policymakers are forcing healthcare providers and public payers to disclose the cost charged and reimbursed to maintain price transparency. Healthcare organizations in Germany spend most of their research funding on adult stem cell research.

Furthermore, Germany spends 11.3% of its GDP on healthcare, which is above the global average. This, in turn, has led to the presence of better healthcare facilities and more advanced research findings on various healthcare issues such as bone marrow transplantation.

Among the 680 centers throughout the Europe, 226 (35%) centers are dedicated to autologous bone marrow transplantation in 2014, with most of the transplants intended for non-malignant disorders. These factors are expected to drive the bone marrow transplantation market in Europe.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4288

APAC Reflects Lucrative Potential for Penetration of Bone Marrow Transplantation Procedures

Rise in the number of bone marrow transplantation centers and expanding donor registry are among the factors expected to reduce the gap between bone marrow transplantation providers and recipients in the Asia Pacific bone marrow transplantation market.

The availability of modern healthcare amenities, along with the presence of several companies engaged in stem cell therapies in China, Australia, and Japan, is expected to be a key factor driving the overall bone marrow transplantation market in Asia Pacific.

After the introduction of alleviating procedures for Peripheral Blood Stem Cell (PBSC) transplant, there has been an increase in the number of allogeneic HSCT procedures using PBSC (64% of the total HSCT) in Australia & New Zealand, which is another factor contributing to the growth of the bone marrow transplantation market in the region.

A survey by the Eastern Mediterranean Blood and Marrow Transplant (EMBMT) Group suggests that non-malignant indications accounted for a 36.5% share of the total bone marrow transplantation activities carried out in the MEA region. Countries such as Dubai and Qatar are undertaking initiatives to develop national bone marrow registries to enhance bone marrow transplantation rates.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4288

The report offers a comprehensive taxonomy of the bone marrow transplantation market based on the transplantation type, indication, end user, and region.

Report Highlights:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Feminine Hygiene Product Market Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash.For More Information

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish Kolte Persistence Market Research Address 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Websitehttps://www.persistencemarketresearch.com

Continue reading here:
Bone Marrow Transplantation Market Size : Technological Advancement and Growth Analysis with Forecast to 2028 - Owned

Global Cryopreservation Equipment in Stem Cells Market 2020 Newest Industry Data, Future Trends and Forecast 2025 – 3rd Watch News

Heres a recently issued report titled Global Cryopreservation Equipment in Stem Cells Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025offers a brief analysis of the market size, demand, supply chain, futuristic trends, and market growth elements. The report highlights restraints, thoughtful insights, and current growth drivers that transform the market in either a positive or negative manner. The report on the global Cryopreservation Equipment in Stem Cells market includes segments by type & application, region, and major players. It explains the scope of different segments and applications that can potentially influence the market in the forecast period from 2020 to 2025. The report studies the market dynamics such as drivers, restraints, opportunities, supply chain, and competitive landscape.

Market segment by manufacturers, this report covers:Thermo Fisher Scientific, praxair, Charter Medicals, Linde Gas Cryoservices

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/131028

The report simply demonstrates accurate statistics and analytical data through graphs, diagrams, pie charts, and other pictorial illustrations. The markets high growth potential will also encourage more start-ups and large firms to enter this market, which will escalate the competitive environment among the players. It also encompasses the analysis of the technical barriers, other issues, and cost-effectiveness affecting the global Cryopreservation Equipment in Stem Cells market. The research study delivers a detailed study of top players, their product description, business overview, and business strategy, as well as future demand, and required raw material.

Regional Analysis:

Regional analysis is presented in the report. This section sheds light on the sales growth of different regional and country-level Cryopreservation Equipment in Stem Cells markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market. The report offers a comprehensive assessment of the growth and other aspects of the market in important countries (regions), including: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East& Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

On the basis of product, the global market is studied across: Liquid Phase, Vapor Phase,

On the basis of the distribution channel, the global Cryopreservation Equipment in Stem Cells market is studied across: Totipotent Stem Cell, Pluripotent Stem Cell,

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/131028/global-cryopreservation-equipment-in-stem-cells-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Key Takeaways of The Market Report:

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us Mark Stone Head of Business Development Phone:+1-201-465-4211 Email:[emailprotected] Web:www.marketandresearch.biz

See original here:
Global Cryopreservation Equipment in Stem Cells Market 2020 Newest Industry Data, Future Trends and Forecast 2025 - 3rd Watch News

2025 Growth: Biotechnology Reagents Market 2020 Research on Import-Export Details, Business Standards and Forecast to 2025 – 3rd Watch News

The study on the Biotechnology Reagents Marketby Brand Essence Market Research is a compilation of systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also offers a precise analysis of the key challenges and growth prospects awaiting key players of the Biotechnology Reagents market, including a concise summary of their corporate strategies and competitive setting.

In 2018, the Global Biotechnology Reagents Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Download Premium Sample of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Sample

Global Biotechnology Reagents Market is valued at USD 71.25 Billion in 2018 and expected to reach USD 121.06 Billion by 2025 with the CAGR of 7.86% over the forecast period.

Increasing prevalence of diseases such as hepatitis B with growing research and development expenditure bybiotechnologytherapeutics and rising number of biotechnology firms globally are expected to boost the market over the forecast period.

Biotechnology reagents are the substances or compounds used to detect or create an additional substance in order to provide a test reading. Hence, the biotechnologies are used in research fields of genetics, molecular biology, diagnosis, immunology, bioscience and in education. The various uses of biotechnology reagents are; fluorescent microscopy, DNA analysis, immuno phenotyping and cell cycle analysis. The biotechnology reagents industry depends on the growth of biotechnology instrumentation market. Biotechnology reagents market includes technologies such as IVD, PCR, transfection, gene expression and cell culture. The basis of technology market is section into analytical reagents and life science reagents. The Life science technologies include in vitro diagnostics, unit culture, polymerase chain reaction and analytical technologies includes flow cytometry, electrophoresis, mass spectrometry and chromatography. The healthcare biotechnology is usually to improve medicines due to the advantages and pieces of knowledge it provides such as understanding the genetic composition of the human species, foundational structure of hereditary diseases manipulation and repairing of damaged genes to cure diseases. As the researchers might see the engineering of a supercharged flu virus as a perfectly reasonable way to better understand and thus fight the flu, the public might see the drawbacks as equally obvious the virus could escape, or someone could weaponize the research and the advanced genetic tools that some are considering for mosquito control could have unforeseen effects, possibly leading to environmental damage. Although the risks of biotechnology have been fretted over for decades, the increasing pace of progress from low cost DNA sequencing to rapid gene synthesis to precision genome editing suggests biotechnology is entering a new realm of maturity regarding both beneficial relevance and more worrisome risks.

Global Biotechnology Reagents Market report is segmented on the basis of type, application, and by regional & country level. Based on type, global biotechnology reagents market is classified as the Life science and analytical. Based upon application, global biotechnology reagents are classified into protein synthesis and purification, gene expression, DNA and RNA analysis and drug testing.

The regions covered in this biotechnology reagents market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of biotechnology reagents is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Biotechnology Reagents Market Report-

Some major key players for Global Biotechnology Reagents Market are Life Technologies, Bio-Rad, Thermo Fisher Scientific, Water Corporation, Sigma-Aldrich Agilent Technologies Inc., Beckman Coulter, Roche, Abbott and others.

Global Biotechnology Reagents Market Dynamics

The rapidly increasing use of biotechnology reagents in therapeutics, basic research and its commercialization are the major factors responsible for the growth of this market. According to the World Health Organization (WHO) in 2017, prevalence of hepatitis B estimated about 27 million people 10.5% of all people estimated to be living with hepatitis B were aware of their infection, while 4.5 million around 16.7% of the people diagnosed were on treatment. Hence, the rising prices of DNA sequencing is predictable to serve this sector as a high impact rendering growth is expected to encourage researchers and manufacturers to increase R&D initiatives targeted at understanding genetic variations and developing therapeutic solutions for chronic diseases with large global prevalence such as cardiovascular diseases, diabetes, and cancer. According to the World Health Organization (WHO) in 2015, the estimates that in 257 million people were living with chronic hepatitis B infection as surface antigen positive, the hepatitis B resulted in an estimated 887 000 deaths, mostly from cirrhosis and hepatocellular carcinoma is primary liver cancer. In addition, the high investments in R&D activities, growing biomedical research, increasing number of biotechnology firms and advancement in stem cell research have contributed to the growth of the biotechnology reagents market.

The biotechnology organizations such as the department of biotechnology (DBT) with government funded institutions and other autonomous organizations representing the biotechnology sector, promote funding to support R&D and innovative produce development endeavors. One of the major challenges faced by this market use of biotechnology reagents in the field of drug discovery is an emerging market where proteomics, DNA chips, combinatorial chemistry, and high throughput screening enjoy the spotlight. In addition, high price of biopharmaceuticals may likely to restrain the growth of the biotechnology reagents market. Moreover, increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology corporation can provide various opportunities for the further growth of the market. The technological advancements and new product launches in health care and life science industries to life science reagents are an integral part of any clinical diagnostic laboratory and pharmaceutical & biotechnology industry. The recent technological advancements in molecular biology, life sciences, and biotechnology has brought about drastic changes in various fields such as medical diagnostics, drug discovery, personalized medicines, forensic sciences, and clinical research & development of the biotechnology reagents market.

Global Biotechnology Reagents Market Regional Analysis

Geographically,North America dominates the global biotechnology reagents market & incurs the highest expenditure for global R&D. According to the World Health Organization (WHO) in 2018, the chronic diseases in the United States are about 133 million Americans 45% of the population have at least one chronic disease. In addition, rising ongoing research in biological sciences considerable investments by various biotechnology companies and the consistently increasing utilization of biotechnology reagents in the market due to the continuing research and outsourcing activities in the field of life science in this region are also supplementing the market growth.

TheAsia Pacific is expected to show a lucrative growth rate during the forecast period due to increasing research and outsourcing activities in life science field. However, the regionlarge population, presence of emerging economies such as China and India, large number of elderly individuals in Japan presents significant opportunities for global players in these countries. Adoption of technologically advanced products in Japan, China, South Korea, Malaysia, and Singapore are likely to fuel the growth of the life science reagents market in this region. Moreover, increased investment by leading pharmaceutical and biotechnology companies in India and China, and rapidly increasing number of hospitals and diagnostic laboratories in the region boost the growth of the biotechnology reagents market in the region.

Key Benefits for Global Biotechnology Reagents Market Report

Global market report covers in depth historical and forecast analysis.Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global market report helps to identify opportunities in market place.Global market report covers extensive analysis of emerging trends and competitive landscape.

By Type

By Application

By Regional & Country Analysis

Table of Contents

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered 1.4 Market Analysis by Type 1.4.1 Global Biotechnology Reagents Market Size Growth Rate by Type (2014-2025) 1.4.2 Topical Products 1.4.3 Botulinum 1.4.4 Dermal Fillers 1.4.5 Chemical Peels 1.4.6 Microabrasion Equipment 1.4.7 Laser Surfacing Treatments 1.5 Market by Application 1.5.1 Global Biotechnology Reagents Market Share by Application (2014-2025) 1.5.2 Hospitals 1.5.3 Dermatology Clinics 1.6 Study Objectives 1.7 Years Considered

2 Global Growth Trends 2.1 Biotechnology Reagents Market Size 2.2 Biotechnology Reagents Growth Trends by Regions 2.2.1 Biotechnology Reagents Market Size by Regions (2014-2025) 2.2.2 Biotechnology Reagents Market Share by Regions (2014-2019) 2.3 Industry Trends 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Opportunities

3 Market Share by Key Players 3.1 Biotechnology Reagents Market Size by Manufacturers 3.1.1 Global Biotechnology Reagents Revenue by Manufacturers (2014-2019) 3.1.2 Global Biotechnology Reagents Revenue Market Share by Manufacturers (2014-2019) 3.1.3 Global Biotechnology Reagents Market Concentration Ratio (CR5 and HHI) 3.2 Biotechnology Reagents Key Players Head office and Area Served 3.3 Key Players Biotechnology Reagents Product/Solution/Service 3.4 Date of Enter into Biotechnology Reagents Market 3.5 Mergers & Acquisitions, Expansion Plans

Read More: https://industrystatsreport.com/Lifesciences-and-Healthcare/Dynamic-Rsearch-on-Biotechnology-Reagents-Market/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

See the rest here:
2025 Growth: Biotechnology Reagents Market 2020 Research on Import-Export Details, Business Standards and Forecast to 2025 - 3rd Watch News

Trending: Viral Inactivation Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026| Danaher, Merck,…

LOS ANGELES, United States: QY Research has recently published a report, titled Global Viral Inactivation Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application.The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Viral Inactivation market. It informs readers about key trends and opportunities in the global Viral Inactivation market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Viral Inactivation market.

Key companies operating in the global Viral Inactivation market include Danaher, Merck, Parker Hannifin, Sartorius, SGS, Charles River Laboratories International, Clean Cells, Rad Source Technologies, Texcell, Viral Inactivated Plasma Systems, Wuxi Pharmatech (Cayman)

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/customize-request/form/1603397/global-viral-inactivation-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Viral Inactivation market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Viral Inactivation Market Segment By Type:

Kits and Reagents, Services, Viral Inactivation Systems and Accessories

Global Viral Inactivation Market Segment By Application:

, Blood and Blood Products, Cellular and Gene Therapy Products, Stem Cell Products, Tissue and Tissue Products, Vaccines and Therapeutics

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Viral Inactivation market.

Key companies operating in the global Viral Inactivation market include Danaher, Merck, Parker Hannifin, Sartorius, SGS, Charles River Laboratories International, Clean Cells, Rad Source Technologies, Texcell, Viral Inactivated Plasma Systems, Wuxi Pharmatech (Cayman)

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1603397/global-viral-inactivation-market

TOC

Table of Contents 1 Market Overview of Viral Inactivation 1.1 Viral Inactivation Market Overview 1.1.1 Viral Inactivation Product Scope 1.1.2 Market Status and Outlook 1.2 Global Viral Inactivation Market Size Overview by Region 2015 VS 2020 VS 2026 1.3 Global Viral Inactivation Market Size by Region (2015-2026) 1.4 Global Viral Inactivation Historic Market Size by Region (2015-2020) 1.5 Global Viral Inactivation Market Size Forecast by Region (2021-2026) 1.6 Key Regions Viral Inactivation Market Size YoY Growth (2015-2026) 1.6.1 North America Viral Inactivation Market Size YoY Growth (2015-2026) 1.6.2 Europe Viral Inactivation Market Size YoY Growth (2015-2026) 1.6.3 China Viral Inactivation Market Size YoY Growth (2015-2026) 1.6.4 Rest of Asia Pacific Viral Inactivation Market Size YoY Growth (2015-2026) 1.6.5 Latin America Viral Inactivation Market Size YoY Growth (2015-2026) 1.6.6 Middle East & Africa Viral Inactivation Market Size YoY Growth (2015-2026) 2 Viral Inactivation Market Overview by Type 2.1 Global Viral Inactivation Market Size by Type: 2015 VS 2020 VS 2026 2.2 Global Viral Inactivation Historic Market Size by Type (2015-2020) 2.3 Global Viral Inactivation Forecasted Market Size by Type (2021-2026) 2.4 Kits and Reagents 2.5 Services 2.6 Viral Inactivation Systems and Accessories 3 Viral Inactivation Market Overview by Type 3.1 Global Viral Inactivation Market Size by Application: 2015 VS 2020 VS 2026 3.2 Global Viral Inactivation Historic Market Size by Application (2015-2020) 3.3 Global Viral Inactivation Forecasted Market Size by Application (2021-2026) 3.4 Blood and Blood Products 3.5 Cellular and Gene Therapy Products 3.6 Stem Cell Products 3.7 Tissue and Tissue Products 3.8 Vaccines and Therapeutics 4 Global Viral Inactivation Competition Analysis by Players 4.1 Global Viral Inactivation Market Size (Million US$) by Players (2015-2020) 4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Viral Inactivation as of 2019) 4.3 Date of Key Manufacturers Enter into Viral Inactivation Market 4.4 Global Top Players Viral Inactivation Headquarters and Area Served 4.5 Key Players Viral Inactivation Product Solution and Service 4.6 Competitive Status 4.6.1 Viral Inactivation Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Danaher 5.1.1 Danaher Profile 5.1.2 Danaher Main Business and Companys Total Revenue 5.1.3 Danaher Products, Services and Solutions 5.1.4 Danaher Revenue (US$ Million) (2015-2020) 5.1.5 Danaher Recent Developments 5.2 Merck 5.2.1 Merck Profile 5.2.2 Merck Main Business and Companys Total Revenue 5.2.3 Merck Products, Services and Solutions 5.2.4 Merck Revenue (US$ Million) (2015-2020) 5.2.5 Merck Recent Developments 5.3 Parker Hannifin 5.5.1 Parker Hannifin Profile 5.3.2 Parker Hannifin Main Business and Companys Total Revenue 5.3.3 Parker Hannifin Products, Services and Solutions 5.3.4 Parker Hannifin Revenue (US$ Million) (2015-2020) 5.3.5 Sartorius Recent Developments 5.4 Sartorius 5.4.1 Sartorius Profile 5.4.2 Sartorius Main Business and Companys Total Revenue 5.4.3 Sartorius Products, Services and Solutions 5.4.4 Sartorius Revenue (US$ Million) (2015-2020) 5.4.5 Sartorius Recent Developments 5.5 SGS 5.5.1 SGS Profile 5.5.2 SGS Main Business and Companys Total Revenue 5.5.3 SGS Products, Services and Solutions 5.5.4 SGS Revenue (US$ Million) (2015-2020) 5.5.5 SGS Recent Developments 5.6 Charles River Laboratories International 5.6.1 Charles River Laboratories International Profile 5.6.2 Charles River Laboratories International Main Business and Companys Total Revenue 5.6.3 Charles River Laboratories International Products, Services and Solutions 5.6.4 Charles River Laboratories International Revenue (US$ Million) (2015-2020) 5.6.5 Charles River Laboratories International Recent Developments 5.7 Clean Cells 5.7.1 Clean Cells Profile 5.7.2 Clean Cells Main Business and Companys Total Revenue 5.7.3 Clean Cells Products, Services and Solutions 5.7.4 Clean Cells Revenue (US$ Million) (2015-2020) 5.7.5 Clean Cells Recent Developments 5.8 Rad Source Technologies 5.8.1 Rad Source Technologies Profile 5.8.2 Rad Source Technologies Main Business and Companys Total Revenue 5.8.3 Rad Source Technologies Products, Services and Solutions 5.8.4 Rad Source Technologies Revenue (US$ Million) (2015-2020) 5.8.5 Rad Source Technologies Recent Developments 5.9 Texcell 5.9.1 Texcell Profile 5.9.2 Texcell Main Business and Companys Total Revenue 5.9.3 Texcell Products, Services and Solutions 5.9.4 Texcell Revenue (US$ Million) (2015-2020) 5.9.5 Texcell Recent Developments 5.10 Viral Inactivated Plasma Systems 5.10.1 Viral Inactivated Plasma Systems Profile 5.10.2 Viral Inactivated Plasma Systems Main Business and Companys Total Revenue 5.10.3 Viral Inactivated Plasma Systems Products, Services and Solutions 5.10.4 Viral Inactivated Plasma Systems Revenue (US$ Million) (2015-2020) 5.10.5 Viral Inactivated Plasma Systems Recent Developments 5.11 Wuxi Pharmatech (Cayman) 5.11.1 Wuxi Pharmatech (Cayman) Profile 5.11.2 Wuxi Pharmatech (Cayman) Main Business and Companys Total Revenue 5.11.3 Wuxi Pharmatech (Cayman) Products, Services and Solutions 5.11.4 Wuxi Pharmatech (Cayman) Revenue (US$ Million) (2015-2020) 5.11.5 Wuxi Pharmatech (Cayman) Recent Developments 6 North America Viral Inactivation by Players and by Application 6.1 North America Viral Inactivation Market Size and Market Share by Players (2015-2020) 6.2 North America Viral Inactivation Market Size by Application (2015-2020) 7 Europe Viral Inactivation by Players and by Application 7.1 Europe Viral Inactivation Market Size and Market Share by Players (2015-2020) 7.2 Europe Viral Inactivation Market Size by Application (2015-2020) 8 China Viral Inactivation by Players and by Application 8.1 China Viral Inactivation Market Size and Market Share by Players (2015-2020) 8.2 China Viral Inactivation Market Size by Application (2015-2020) 9 Rest of Asia Pacific Viral Inactivation by Players and by Application 9.1 Rest of Asia Pacific Viral Inactivation Market Size and Market Share by Players (2015-2020) 9.2 Rest of Asia Pacific Viral Inactivation Market Size by Application (2015-2020) 10 Latin America Viral Inactivation by Players and by Application 10.1 Latin America Viral Inactivation Market Size and Market Share by Players (2015-2020) 10.2 Latin America Viral Inactivation Market Size by Application (2015-2020) 11 Middle East & Africa Viral Inactivation by Players and by Application 11.1 Middle East & Africa Viral Inactivation Market Size and Market Share by Players (2015-2020) 11.2 Middle East & Africa Viral Inactivation Market Size by Application (2015-2020) 12 Viral Inactivation Market Dynamics 12.1 Industry Trends 12.2 Market Drivers 12.3 Market Challenges 12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach 14.1.1 Research Programs/Design 14.1.2 Market Size Estimation 14.1.3 Market Breakdown and Data Triangulation 14.2 Data Source 14.2.1 Secondary Sources 14.2.2 Primary Sources 14.3 Disclaimer 14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Link:
Trending: Viral Inactivation Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026| Danaher, Merck,...

Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra – Endpoints News

Now that the EMA has elbowed Novartis application for Xiidra off the table, the reverberations are being felt at Takeda.

The pharma giant noted early Monday that it will recognize a loss of $200 million for the current quarter after the news hit late last week that the European regulator had decided that the eye drug they sold to Novartis for $3.4 billion in cash and $1.9 billion in milestones hadnt made its case on efficacy. The drug has been marketed in the US now for 4 years, and Takeda picked it up in the $62 billion Shire buyout and then promptly sold it off to Novartis.

That decision at the EMA is hitting the $1.9 billion in potential sales milestones, now that the European market is off the table. The continental regulator was clearly unimpressed by the data for Xiidra, and became skeptical over the way the control arm was handled by Shire.

In explaining the withdrawal, the EMA noted:

The Agency considered that the effectiveness of Xiidra was not demonstrated across different symptoms of dry eye disease. Although some effect was seen in the reduction of eye dryness, the improvement was not considered clinically significant. In addition, although Xiidra was intended to be used in patients with more severe disease in whom artificial tears had not been sufficient in improving the condition, the Agency had some concerns about how these patients were to be selected, and noted that the studies had compared Xiidra with the vehicle, and had not used artificial tears in an optimal way. The Agency also noted that there were no data on the effect of long-term treatment with Xiidra despite eye dryness being a chronic (long-lasting) disease.

The drug, as Novartis explained, is designed to block the interaction between LFA-1 1 and ICAM-1 2, inhibiting T cell recruitment and activation and reducing pro-inflammatory cytokine release.

Original post:
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra - Endpoints News

COVID-19: Plasma therapy vs stem cell therapy, what’s the difference? – Gulf News

Image Credit: Gulf News

DUBAI: Plasma and stem cell (SC) therapies are two of the emerging star treatments being used in the fight against the SARS-CoV-2 virus.

Against COVID-19, they're considered stop-gap measures, while the world awaits a vaccine. Both, however, have proven effective against severe cases infections caused by the novel coronavirus, which has already killed over 502,000 and infected 10.1 million as of Monday (June 29, 2020).

Plasma and SC therapies have similarities, as well as obvious differences. We outline them below:

Both plasma and stem cell therapies rely on rejuvenating damaged body tissue. Theyboth form part of what's described as regenerative medicine, a fast-emerging branch of medical science involving techniques thathelp restore the functionof tissues or organs.

Being regenerative treatments (or therapies), they encourage your body to use its natural abilities to heal injuries or other types of tissue damage or inflammation.

The journal Platelets refer to platelet-rich plasma (PRP) and stem cell (SC) therapies as the "mainstream medical technologies" to repair and rejuvenate a damaged tissue or organ caused by injury or chronic diseases.

Plasma-rich platelets are components of blood that contain platelet concentrations above the normal level.

Platelets are the frontline workers in carrying out a healing response to injuries. They release growth factors for tissue repair.Plasma therapy uses the liquid portion of blood (plasma, yellowish) which includes a higher concentration of platelets the part of blood that contributes to clotting and healing.

Stem cells, on the other hand, are generic cells. They are the prime cells -- unspecialised, undifferentiated, immature cells. Based on specific stimuli, they can divide and differentiate into specific type of cells and tissues.

Stem cells are the basic, generic building blocks of life. In a sense, they unspecialised, undifferentiated, immature cells. They can divide and differentiate into specific type of cells and tissues, based on based on specific stimuli.

Its this ability to differentiate into other types of cell that make stem cells interesting to medical science.

In adults, they are usually obtained from bone marrow. In infants, stem cells are usually taken from the umbilical cord.

Scientists have found stem cells present in blood vessels, the brain, skeletal muscles, skin and the liver.

They can be difficult to find and work with. Stem cells are also categorised by their potential to differentiate into different cell types. These include, pluripotent and multipotent stem cells.

SCs are generic (or primitive) cells obtained either from embryos or from the adult tissues, that have the capacity of self-renewal and can differentiate into as many as 200 different cell types of the adult body.

SC also produces certain growth factors and cytokines that accelerate the healing process at the site of tissue damage. Cytokines are secreted by certain cells of the immune system and have an effect on other cells. SC is used to treat degenerative and inflammatory conditions by replacing the damaged cells in virtually any tissue or organ, where PRP applications serve no benefit.

In the UAE, a medical research team has developed a first-in-the-world technique using inhaled stem cells that harvestedfrom the patients themselves. Following the initial success of the technique in 73 patients, the procedure has been ramped up.

In May, the ADSCC team, led by Dr Yendry Ventura, unveiled the new treatment. The UAECell19 is an autologous (cells obtained from the same individual)stem cells therapy which helped cut hospital stay from 22 days to six, relative to patients who were given standard treatment.

According to the Abu Dhabi team, patients given the stem cell therapy were up to 3.1x more likely to recover in less than seven days compared to those given standard treatment.

Researchers also stated that 67% of the patients who received the stem cells treatment owed this recovery to the new treatment.

ADSCC has secured a patent for UAECell19. Protection of the intellectual property rights for the therapy opens doors for it tobe shared more widely so more patients can benefit.

Plasma is the liquid portion of whole blood. It is composed largely of water and proteins, and it provides a medium for red blood cells, white blood cells and platelets to circulate through the body.

Convalescent refers to a person recovering from an illness or medical treatment.

Convalescent plasma, also known as immunoglobulins, is plasma taken from the blood of a person who has recovered from a disease.

Research shows that recovered COVID-19 patients develop antibodies in the blood against the virus. Antibodies are proteins that might help fight the infection.

Platelets, a component of the blood, are repair agents. They are frontliners in the healing response to injuries. Platelets are also called thrombocytes, blood cells that trigger blood clotting and other necessary growth healing functions.

PLATELET FACTS

[] When the platelet count is less than 50,000, bleeding is likely to be more serious if you're cut or bruised.

[] Some people make too many platelets. They can have platelet counts from 500,000 to more than 1 million.

PRP is a component of blood that contains platelet concentrations above the normal level -- usually five times higher concentrations of platelets above the normal values. It includes platelet-related growth factors and plasma-derived fibrinogen (a blood plasma protein that's made in the liver), among others.

Yes. Convalescent plasma hasbeen used as a last resort to improve the survival rates of patients with SARS (2003), as well as the "Spanish Flu" (1918-1920), as well as other infectious diseases.The Lancetcitesseveral studies that showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with it.

It's been gaining ground in the COVID-19 fight around the world. In the last few weeks, convalescent plasma therapy has helped treat at least 170 patients at the Infectious Disease Department at Rashid Hospital in Dubai.

THROMBOCYTOPENIA

[] This can be caused by many conditions by medicines, cancer, liver disease, pregnancy, infections (including COVID-19), and an abnormal immune system.

If you are one of the thousands of patients fully-recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma. That's because you fought the infection, your plasma now contains COVID-19 antibodies.

These antibodies provided one way for your immune system to fight the virus when you were sick, so your plasma may be able to be used to help others fight off the disease.

Yes, you are. Health authorities, including the US Food and Drug Administration, encourage people who have fully recovered from COVID-19 for at least two weeks to consider donating plasma.

You can help save the lives of other patients.

However, you must first undergo some tests to check if you're eligible to meet donor criteria. Doctors will determine that. COVID-19 convalescent plasma must only be collected from recovered individuals if you are eligible.

A lab test must document a prior diagnosis of COVID-19. In general, FDA protocol requires individuals to have complete resolution of symptoms for at least 14 days prior to donation.

No. The FDA guideline states: A negative lab test for active COVID-19 disease is not necessary to qualify for donation.

You shouldconsider donating blood. One blood donation can save up to three lives.

View post:
COVID-19: Plasma therapy vs stem cell therapy, what's the difference? - Gulf News

Novel coronavirus infection might trigger type-1 diabetes – The Hindu

Diabetes poses one of the key risk factors for developing severe COVID-19, and chances of dying are elevated in people with diabetes. Now, there is growing evidence that novel coronavirus might actually be triggering diabetes in some people who have so far remained free of it. These patients typically develop type-1 diabetes. The virus seems to be causing diabetes spontaneously in people.

These patients typically develop type-1 diabetes, which is caused when the bodys immune system plays rogue and begins to attack and destroy the beta cells, which produce the hormone insulin in the pancreas. With the destruction of beta cells, the amount of insulin produced is reduced, and hence, the ability of the body to control blood sugar is compromised leading to type-1 diabetes.

The 2002 SARS coronavirus, too, caused acute-onset diabetes in patients. Like the 2002 SARS coronavirus, the SARS-CoV-2 virus, too, binds to ACE2 receptors that are found on many organs involved in controlling blood sugar, including the liver and pancreatic beta cells, and subsequently infects the cells in the organs.

In a letter published in The New England Journal of Medicine, the researchers write: There is a bidirectional relationship between COVID-19 and diabetes. On the one hand, diabetes is associated with an increased risk of severe COVID-19. On the other hand, new-onset diabetes and severe metabolic complications of preexisting diabetes have been observed in patients with COVID-19.

However, more evidence is needed to conclusively prove that COVID-19 indeed causes type-1 diabetes. It is also not clear if the acute-onset diabetes in COVID-19 patients will be permanent or transient. The is no clarity whether people who are borderline type-2 develop the disease.

The COVID-19 patients who develop diabetes have extremely high levels of blood sugar and ketones. When there is insufficient insulin produced, breaking down the sugar present in the blood is compromised leading to high levels of sugar. At the same time, the body begins to turn to alternative sources of fuel, which in this case are ketones. A study found 42 of 658 patients presented with ketosis on admission. Patients with ketosis were younger (median age 47). Ketosis increased the length of hospital stay and mortality, the researchers found.

Using human pluripotent stem cells, researchers grew miniature liver and pancreas and found that both the organs were permissive to SARS-CoV-2 infection. In particular, they found the pancreatic beta cells were infected by coronavirus. ACE2 is expressed in human adult alpha and beta cells. While the beta cells produce insulin which reduces the sugar level in the blood, the alpha cells produce glucagon, which increases the blood sugar. A fine balance between the two helps maintain the blood sugar level.

The researchers transplanted the miniature pancreatic endocrine cells produced using human stem cells into mice. Two months later, they examined the xenografted pancreas and found ACE2 receptors on beta and alpha cells. When the mice were infected with coronavirus, they found the beta cells were infected by the virus. Thus the virus is capable of damaging the cells that control blood sugar thus triggering acute-onset of type-1 diabetes.

According to Nature News, a global database to collect information on people with COVID-19 and high blood-sugar levels who previously do not have a history of elevated blood sugar levels has been initiated. The researchers hope to use the cases to understand whether SARS-CoV-2 can induce type 1 diabetes or a new form of the disease, Nature News says. Researchers want to use the database to understand if the acute-onset diabetes is permanent and people who are borderline type-2 develop the disease.

You have reached your limit for free articles this month.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Read this article:
Novel coronavirus infection might trigger type-1 diabetes - The Hindu